Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that the U.S. Food and Drug Administration has ...
Bausch + Lomb (NYSE:BLCO) received US FDA clearance for its Bi-Blade+ dual-port vitrectomy cutter and Adaptive Fluidics update, expanding its retina surgery toolkit. The company launched the enVista ...
FDA clearance for its Bi-Blade+ advanced dual-port vitrectomy cutter and Adaptive Fluidics update for the Stellaris Elite ...
When preparing for cataract surgery in patients with retinal pathologies, ophthalmologists must be sure to set reasonable ...
For a mid-sized party that earned its place in Indian political chronicles by claiming and retaining Delhi in the 2015 and ...
Correspondence to Dr Yoshihiro Takamura, Department of Ophthalmology, Faculty of Medical Sciences, University of Fukui, Yoshida, Fukui 910-1193, Japan; ytakamura{at}hotmail.com Background/Aims To ...
Patients with vitiligo face a higher risk for diabetic retinopathy, glaucoma, AMD, and vitreous hemorrhage, per ASCRS 2026 ...
My niece was diagnosed with birdshot chorioretinopathy.
View Bausch + Lomb Corporation BLCO stock quote prices, financial information, real-time forecasts, and company news from CNN.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results